# Olaris, Inc.

> Olaris is a Framingham, Massachusetts precision-diagnostics company that combines metabolomics, machine learning and biological interpretation to develop clinical tests and biomarker services. Its first commercial product, myOLARIS-KTdx, profiles urinary metabolites to help transplant clinicians surveil kidney-graft injury, while additional assays address medication adherence, pediatric graft injury and cardiovascular risk after liver transplant.

- **Founded:** 2014
- **Headquarters:** Framingham, United States
- **Founders:** Elizabeth O'Day, PhD (CEO and Founder)
- **Team size:** Approximately 19 employees; LinkedIn lists a company-size range of 11-50.
- **Products:** myOLARIS-KTdx, myOLARIS-MMF Drug Signature, myOLARIS-pKTdx, myOLARIS-CVD LTdx, Biomarker Services
- **Notable:** Received AMA PLA code 0542U for myOLARIS-KTdx, effective April 1, 2025., Runs KTdx through a CLIA-certified laboratory with a stated turnaround time of about 3-5 business days after sample receipt., Published a 2025 peer-reviewed study of urinary metabolite signatures for kidney-graft injury in iScience.

## Products & services

- **myOLARIS-KTdx** — A non-invasive, urine-based laboratory-developed test for surveillance of kidney-graft injury in adult transplant recipients. NMR profiling of 84 urinary metabolites is combined with patient data, BK-virus quantification and serum creatinine to produce a similarity-based score for clinician interpretation.
- **myOLARIS-MMF Drug Signature** — A urine-based NMR laboratory-developed test that detects metabolites of mycophenolate mofetil to provide a direct readout related to medication adherence after transplant.
- **myOLARIS-pKTdx** — An in-development urine assay intended to distinguish multiple biopsy-confirmed kidney-graft injury phenotypes in pediatric kidney-transplant recipients.
- **myOLARIS-CVD LTdx** — An in-development plasma assay intended to identify liver-transplant recipients at increased risk of cardiovascular complications.
- **Biomarker Services** — Collaborative metabolomics research for pharmaceutical companies, biotech firms, nonprofit foundations and academic institutions, spanning study design, metabolite profiling, signature discovery and biological interpretation.

## Achievements

- Received AMA PLA code 0542U for myOLARIS-KTdx, effective April 1, 2025.
- Runs KTdx through a CLIA-certified laboratory with a stated turnaround time of about 3-5 business days after sample receipt.
- Published a 2025 peer-reviewed study of urinary metabolite signatures for kidney-graft injury in iScience.
- Published standardized NMR and triple-quadrupole mass-spectrometry metabolomics methods in Metabolites in 2024.
- Secured strategic investment from Labcorp and Bruker in 2025.
- Announced a national commercial-access collaboration with Labcorp in 2026.
- Selected for the inaugural Massachusetts Life Sciences Center MassNextGen program in 2018.
- Founder Elizabeth O'Day was named to Boston Business Journal's 40 Under 40 in 2020 and Worcester Business Journal's 40 Under Forty in 2023.

## Latest updates

- **2026-06** — Olaris and Labcorp announced a commercial collaboration intended to make KTdx orderable through Labcorp workflows and accessible through its national patient-service network later in 2026.
- **2026-06** — Olaris presented early data at the American Transplant Congress on pediatric kidney-graft injury and cardiovascular risk after liver transplant.
- **2026-05** — Olaris publicly introduced the myOLARIS-MMF Drug Signature as a urine-based LDT for direct monitoring of mycophenolate mofetil metabolites.
- **2025-05** — Bruker made a strategic investment as part of Olaris's Series B-1 financing.
- **2025-04** — Labcorp made a strategic investment in Olaris following the award of PLA code 0542U.
- **2025-01** — Olaris announced that the AMA granted a unique PLA code for KTdx, effective April 1, 2025.

## Links

- Website: https://www.myolaris.com/
- LinkedIn: https://www.linkedin.com/company/olarisbor
- Twitter/X: https://twitter.com/OlarisBoR
- Instagram: https://www.instagram.com/myolaris/
- Facebook: https://www.facebook.com/olarisBoR/

---

Profile page: https://yespress.io/olaris-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-20